With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including Switzerland and Canada.

(Reuters) -The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU ...

When it was sold in the U.S., Blenrep carried an FDA boxed warning for its ocular toxicity risks. GSK, optimistic about a global comeback, has put the drug’s peak sales estimate at more than 3 ...

Key Takeaways Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its ...

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA, a cell-surface protein that plays an important role in the survival of plasma cells and is expressed on multiple ...

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed 1,2,3 First and only approved anti-BCMA-ADC for the treatment of multiple myeloma in ...

Treatment of Blenrep (belantamab mafodotin) in combination with Velcade (bortezomib) plus dexamethasone significantly improved progression-free survival compared with standard treatment for patients ...

Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F. The Food and Drug Administration ...

Though Blenrep is also approved in Europe, the drug’s sales have been significantly impacted owing to its withdrawal from the U.S. markets. Blenrep sales plunged 67% at constant exchange rate in ...

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome ...